Treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate at a primary care unit in Brazil
Abstract
Intralesional (IL) meglumine antimoniate (MA) is recommended for cutaneous leishmaniasis (CL) treatment. The lack of resources in primary health care units usually hinders monitoring of adverse events, handling of comorbidities, and use of second-line drugs. We report six CL patients treated with subcutaneous IL MA (due to contraindication or adverse effects to systemic MA) in a primary health care unit. The procedure was repeated every two weeks up to the epithelialization of the lesion. All treated lesions epithelialized. The only adverse effect was moderate local eczema. IL MA treatment seems to be a simple, efficient and safe therapy for CL.Downloads
Download data is not yet available.
Downloads
Published
2017-10-24
How to Cite
Duque, M. C. de O., Quintão, J. J., Gonçalves, L. F., Gomes, C., de Almeida, H. L., Silveira, E. S., Horta, A. P. A., Lyra, M. R., Pimentel, M. I. F., Vasconcellos, Érica de C. F. e, Saheki, M. N., Marzochi, M. C. de A., Valete-Rosalino, C. M., & Schubach, A. de O. (2017). Treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate at a primary care unit in Brazil. Revista De Medicina E Saúde De Brasília, 6(2). Retrieved from https://portalrevistas.ucb.br/index.php/rmsbr/article/view/8520
Issue
Section
Relato de Caso